TIM-3 Inhibition Enhances Tumor Progression and Metastasis: A Paradoxical Immune Checkpoint Response

Syngeneic breast tumors were developed by inoculating of 4T1 cells, into the left flank of female Balb/c mice. When tumor volume reached 200-250 mm3, mice were selected randomized way to receive the treatment of anti-TIM-3 monoclonal antibody (mAb) (Clone: RMT3-23, BioXcell, cat. # BE0115, RRID: AB_10949464). Anti-TIM-3 mAb (250 µg/injection) was administered via the intraperitoneal (i.p.) route. Primary tumors were allowed to developed for up-to 40 days. Primary tumor histology, liver metastasis, and serum cytokine and tumor tissue proteome were analysed and compared between the control tumor and TIM-3 antibody treated tumor.

本研究通过向雌性BALB/c小鼠左侧胁部接种4T1细胞，构建同系乳腺癌移植瘤模型。当肿瘤体积达到200~250 mm³时，采用随机分组方式将小鼠分配至抗TIM-3单克隆抗体（monoclonal antibody, mAb）干预组：该抗体由BioXCell公司生产，克隆号为RMT3-23，货号为BE0115，研究资源标识符（RRID）为AB_10949464。抗TIM-3 mAb以腹腔注射（intraperitoneal, i.p.）途径给药，单次注射剂量为250 μg。原代肿瘤的建模周期最长为40天。随后对对照组与抗TIM-3抗体处理组的原代肿瘤组织学特征、肝脏转移情况、血清细胞因子水平及肿瘤组织蛋白质组进行检测分析，并开展组间比较。